AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.42
-0.03 (-0.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.45
Open12.50
Bid12.35 x 1200
Ask12.49 x 1400
Day's Range12.00 - 12.67
52 Week Range9.83 - 25.22
Volume1,015,108
Avg. Volume1,177,465
Market Cap556.37M
Beta1.09
PE Ratio (TTM)N/A
EPS (TTM)-3.34
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.20
Trade prices are not sourced from all markets
  • Benzinga2 days ago

    Achaogen In The Spotlight Ahead of FDA Verdict On Plazomicin

    Plazomicin is Achaogen's lead product candidate. It is a semisynthetic aminoglycoside antibiotic being developed for infections due to multidrug-resistant Enterobacteriaceae, especially carbapenem-resistant Enterobacteriaceae, or CRE. Achaogen submitted a new drug application for plazomicin to the FDA in October 2017 for treating complicated urinary tract infections, or cUTIs, including polynephritis and blood stream infections.

  • Why Did Achaogen Inc’s’ (NASDAQ:AKAO) Insiders Buy Up More Shares?
    Simply Wall St.4 days ago

    Why Did Achaogen Inc’s’ (NASDAQ:AKAO) Insiders Buy Up More Shares?

    Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. Achaogen’s insiders have investedRead More...

  • GlobeNewswire13 days ago

    Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting

    SOUTH SAN FRANCISCO, Calif., June 11, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today ...

  • Forbes16 days ago

    An Unlikely Biotech Investor: The Government

    Walking around the convention floor at BIO was a remarkable experience this week in Boston.  Not only were there an endless number of human health companies present, there were also animal health companies.  States like Georgia, New Jersey, Maryland, Hawaii were also present, and countries too, among them Estonia, Japan, Switzerland, and Canada was a major sponsor of this year’s conference.  The message at BIO was clear: The world needs biotech.

  • ACCESSWIRE23 days ago

    Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).

  • GlobeNewswirelast month

    Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting

    SOUTH SAN FRANCISCO, Calif., May 24, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today announced ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AKAO earnings conference call or presentation 4-May-18 12:30pm GMT

    Q1 2018 Achaogen Inc Earnings Call

  • ACCESSWIRE2 months ago

    Blog Exposure - Lexicon Pharma’s New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LXRX as the Company's latest news hit the wire. On May 04, 2018, the Company announced that new XERMELO® (telotristat ethyl) data from the randomized, double-blind, placebo-controlled Phase-3 TELESTAR study were published in March issue of Clinical Therapeutics. The publication provides the first report of the effects of XERMELO® on changes in weight in patients with neuroendocrine tumors (NETs) and carcinoid syndrome that participated in the Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome (TELESTAR) study.

  • Associated Press2 months ago

    Achaogen: 1Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.06. Losses, adjusted for non-recurring costs and to extinguish debt, were 98 cents per share. The results ...

  • GlobeNewswire2 months ago

    Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update

    --FDA Advisory Committee voted in favor of plazomicin for treatment of adults with complicated urinary tract infections--. --Conference call today at 8:30 a.m. Eastern Time--. SOUTH SAN FRANCISCO, Calif., ...

  • ACCESSWIRE2 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:30 AM Eastern Time. To listen ...

  • Benzinga2 months ago

    Why Achaogen Shares Are Getting Crushed On Plazomicin FDA News

    Achaogen Inc (NASDAQ: AKAO) shares are tumbling Thursday after a mixed FDA panel vote on Plazomicin, its lead candidate to treat serious bacterial infections due to multidrug-resistant enterobacteriaceae. The FDA's Antimicrobial Drugs Advisory Committee voted 11-4 that the company failed to provide substantial evidence of safety and effectiveness of its plazomicin to treat bloodstream infections in patients with limited or no treatment options. The EPIC trial is evaluating the pipeline candidate for complicated UTIs, and is a single pivotal trial supporting a New Drug Application in the U.S. and Marketing Authorization Application, or MAA, in Europe.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock was trading lower ...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...

  • ACCESSWIRE2 months ago

    Why the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public Company

    Robert Duggan's very public success with PCYC from $1 to $260 is a recent example. The Mayo Clinic is one of the most prestigious healthcare systems globally, and this institute is a 10% holder of stock in NeuroOne (NMTC), a company that develops technology for use in neurologic conditions. The company is completely undiscovered by public investors yet has a few big events coming up in the next 12 months, including a filing with the FDA (food and drug administration) for the approval of their first medical device.

  • Peninsula drug developer's stock plunges, but its antibiotic still could win FDA approval
    American City Business Journals2 months ago

    Peninsula drug developer's stock plunges, but its antibiotic still could win FDA approval

    An FDA advisory committee recommended approving Achaogen's plazomicin for urinary tract infections but not for bloodstream infections, which investors see as the bigger market opportunity. But there's still hope that the antibiotic could be approved.

  • GlobeNewswire2 months ago

    Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections

    1. Has the applicant provided substantial evidence of the safety and effectiveness of plazomicin for the treatment of complicated urinary tract infections? 2. Has the applicant provided substantial evidence of the safety and effectiveness of plazomicin for the treatment of bloodstream infections in patients with limited or no treatment options? “We are encouraged by the Committee's unanimous vote in favor of plazomicin for complicated urinary tract infections (cUTI).

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus, and First Defiance Financial — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cohen ...

  • GlobeNewswire2 months ago

    Achaogen Stock Trading Halted Today

    SOUTH SAN FRANCISCO, Calif., May 02, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today announced ...

  • Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals
    SmarterAnalyst2 months ago

    Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals

    Will the FDA writing on the wall bode well for three pharmaceutical firms raring for a PDUFA nod this summer? Achaogen (NASDAQ:AKAO) complicated urinary tract infection cUTI asset plazomicin, Scpharmaceuticals (NASDAQ:SCPH) heart treatment Furoscix, and TherapeuticsMD (NASDAQ:TXMD) vulvar vaginal atrophy (VVA) have attracted a team of bulls rooting for the success of these candidates ahead of the big decisions due from the FDA panel. Biotech investor anticipation will be high come Wednesday, where Achaogen's plazomicin will be in the spotlight.

  • Options Traders Expect Huge Moves in Achaogen (AKAO) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Achaogen (AKAO) Stock

    Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire2 months ago

    Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections

    --CARB-X funding to support Achaogen’ s early-stage aminoglycoside program developing antibiotics for difficult to treat infections that are associated with high mortality--. --Awarded Up to $2.4 million ...

  • GlobeNewswire2 months ago

    Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018

    SOUTH SAN FRANCISCO, Calif., April 25, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today ...

  • GlobeNewswire2 months ago

    Achaogen Highlights Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    --Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae--. SOUTH SAN FRANCISCO, Calif., April 23, ...

  • An In-Depth Look at Achaogen’s Cash Flow
    Market Realist2 months ago

    An In-Depth Look at Achaogen’s Cash Flow

    Achaogen (AKAO) used $95.2 million in operating activities in fiscal 2017 compared to $46.9 million in fiscal 2016. Achaogen’s stock-based compensation expenses were $14.2 million, and its net change in operating assets and liabilities was $16.1 million in fiscal 2017. Achaogen raised $130.4 million from financing activities in fiscal 2017 compared with $135.4 million in fiscal 2016.